Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
AbstractAims/hypothesisFenofibrate has been noted to cause an elevation in serum creatinine in some individuals. Participants in the Action to Control Cardiovascular Risk in Diabetes Lipid Study were studied to better characterise who is at risk of an increase in creatinine level and to determine whether those with creatinine elevation have a differential risk of adverse renal or cardiovascular outcomes.MethodsA fenofibrate-associated creatinine increase (FACI) was defined as an increase in serum creatinine of at least 20% from baseline to month 4 in participants assigned to fenofibrate. Baseline patient characteristics, and baseline and 4-month drug, clinical, laboratory characteristics and study outcomes were examined by FACI status.ResultsOf the sample, 48% of those randomised to receive fenofibrate had at least a 20% increase in serum creatinine within 4 months. In multivariable analysis, participants who were older, male, used an ACE inhibitor at baseline, used a thiazolidinedione (TZD) at 4 months post-randomisation, had baseline CVD, and had lower baseline serum creatinine and LDL-cholesterol levels were all more likely to meet the criteria for FACI. Participants in the FACI group were also more likely to have a decrease in their serum triacylglycerol level from baseline to 4 months. No differences in study outcomes were seen by FACI criteria.Conclusions/interpretationSeveral characteristics predict a rapid rise in serum creatinine upon starting fenofibrate. Participants who met the criteria for FACI also had a greater change in triacylglycerol levels. In the setting of careful renal function surveillance and reduction of fenofibrate dose as indicated, no increase in renal disease or cardiovascular outcome was seen in those individuals demonstrating FACI. Trial registration: ClincalTrials.gov: NCT00000620 Funding: The ACCORD Trial was supported by grants (N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184, IAA-Y1-HC-9035 and IAA-Y1-HC-1010) from the National Heart, Lung, and Blood Institute; by the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Eye Institute; by the Centers for Disease Control and Prevention; by General Clinical Research Centers and by the Clinical and Translational Science Awards. Abbott Laboratories, Amylin Pharmaceutical, AstraZeneca Pharmaceuticals LP, Bayer HealthCare LLC, Closer Healthcare, GlaxoSmithKline Pharmaceuticals, King Pharmaceuticals, Merck, Novartis Pharmaceuticals, Novo Nordisk, Omron Healthcare, sanofi-aventis US and Takeda Pharmaceuticals provided study medications, equipment or supplies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A note on a general definition of the coefficient of determination
NAGELKERKE, N. J. D. (1991) · Biometrika · doi:10.1093/biomet/78.3.691 · Cited by 5,927 · cited 1×
“9% [28]) OR for 1 SD increase for continuous factors Variable OR (95% CI) p value”
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 2×
“The occurrence of micro- and macroalbuminuria was significantly reduced by fenofibrate treatment in the full ACCORD Lipid Study cohort [14].”
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods
Buse, J. B. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.003 · Cited by 661
Self-citationon behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371 · cited 2×
“brate had an eGFR closer to baseline values than did participants randomised to placebo [23].”
Ansquer, J.-C., Foucher, C., Rattier, S., Taskinen, M.-R., & Steiner, G. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.11.004 · Cited by 264
Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine
Hottelart, C., El Esper, N., Rose, F., Achard, J.-M., & Fournier, A. (2002) · Nephron · doi:10.1159/000064083 · Cited by 186
Fibrate‐induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Broeders, N., Knoop, C., Antoine, M., Tielemans, C., & Abramowicz, D. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.12.1993 · Cited by 163 · cited 5×
“Although initial case reports of increased creatinine with fenofibrate treatment included patients with impaired renal function, renal transplant and proteinuria, previous studies have not determined whether impaired renal function is a predictor of creatinine elevation following fenofibrate therapy [4, 9, 10].”
InfluentialEffect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People
Ansquer, J.-C., Dalton, R. N., Caussé, E., Crimet, D., Le Malicot, K., & Foucher, C. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.01.014 · Cited by 107 · cited 4×
“In a crossover study of fenofibrate and placebo, Ansquer et al did not find a significant change in GFR as measured by inulin clearance, tubular creatinine secretion as measured by urinary/plasma creatinine to urinary/plasma inulin ratio, or total creatinine excretion as measured by 24 h urinary creatinine collection…”
InfluentialGinsberg, H. N., Bonds, D. E., Lovato, L. C., Crouse, J. R., Elam, M. B., Linz, P. E., O’Connor, P. J., Leiter, L. A., Weiss, D., Lipkin, E., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.024 · Cited by 95
Self-citation
Cited by
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Dubois, V., Eeckhoute, J., Lefebvre, P., & Staels, B. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88894 · Cited by 383
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
Metadata
- Authors
- Bonds, D. E., Craven, T. E., Buse, J., Crouse, J. R., Cuddihy, R., Elam, M., Ginsberg, H. N., Kirchner, K., Marcovina, S., Mychaleckyj, J. C., O’Connor, P. J., & Sperl-Hillen, J.-A.
- Venue
- Diabetologia
- Published
- 2012-03-27
- Volume
- 55
- Issue
- 6
- Pages
- 1641-1650
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1980316499
- Cited by
- 64
- References
- 11
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. https://app.cochat.ai/papers/10.1007/s00125-012-2524-2
- The paper
- Bonds, D. E., Craven, T. E., Buse, J., Crouse, J. R., Cuddihy, R., Elam, M., Ginsberg, H. N., Kirchner, K., Marcovina, S., Mychaleckyj, J. C., O’Connor, P. J., & Sperl-Hillen, J.-A. (2012). Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia. https://doi.org/10.1007/s00125-012-2524-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.